{
    "clinical_study": {
        "@rank": "89290", 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the safety and favorable immune response to an\n      anti-streptococcal vaccine (a vaccine that treats a common bacterial infection) in healthy\n      non-pregnant women.\n\n      Group B Streptococcus (GBS) continues to be the single most frequent cause of\n      life-threatening bacterial infection during the first 2 months of life. Further, GBS\n      pregnancy-related morbidity afflicts more than 50,000 women annually in the US. Therefore,\n      active immunization of women is an appealing strategy for the prevention of GBS disease in\n      pregnant women and their infants during the first 3 months of infant life."
        }, 
        "brief_title": "Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines", 
        "completion_date": "November 2005", 
        "condition": [
            "Bacterial Infections", 
            "Group B Streptococcus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bacterial Infections", 
                "Tetanus"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this study 65 healthy, non-pregnant women will receive a single dose of one of two\n      anti-streptococcal vaccinations. Both types of vaccinations are given in upper arm by\n      injection into the muscle. To assess the vaccine effectiveness, patients have blood drawn\n      and examined at weeks 4, 8 and 26, post-vaccination."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "This information currently is not available."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "65", 
        "firstreceived_date": "January 18, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00008853", 
            "org_study_id": "DMID 97-004"
        }, 
        "intervention": [
            {
                "intervention_name": "GBS III-TT-SSI", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "GBS III-TT-MPHL", 
                "intervention_type": "Biological"
            }
        ], 
        "keyword": "Clinical Evaluation", 
        "lastchanged_date": "August 26, 2010", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10011"
                }, 
                "name": "AIDS Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00008853"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2005"
    }, 
    "geocoordinates": {
        "AIDS Ctr": "40.714 -74.006"
    }
}